Celldex Therapeutics Inc. (NASDAQ:CLDX) traded up 2.5% during trading on Friday . The stock traded as high as $4.62 and last traded at $4.59, with a volume of 691,195 shares trading hands. The stock had previously closed at $4.48.

Several equities research analysts have commented on the company. Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, June 7th. Wedbush reaffirmed a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a research report on Friday, May 6th. Roth Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, April 19th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $4.00 price target on shares of Celldex Therapeutics in a research report on Friday, May 6th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Celldex Therapeutics currently has a consensus rating of “Hold” and an average price target of $14.11.

The stock’s market capitalization is $462.00 million. The stock’s 50 day moving average is $4.46 and its 200-day moving average is $6.04.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). During the same quarter in the previous year, the company posted ($0.33) EPS. The firm earned $1.30 million during the quarter, compared to the consensus estimate of $1.06 million. The firm’s revenue was up 160.0% on a year-over-year basis. Analysts predict that Celldex Therapeutics Inc. will post ($1.36) earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have recently made changes to their positions in CLDX. TSP Capital Management Group LLC raised its position in shares of Celldex Therapeutics by 0.8% in the fourth quarter. TSP Capital Management Group LLC now owns 831,648 shares of the biopharmaceutical company’s stock valued at $13,040,000 after buying an additional 6,967 shares during the last quarter. Bedell Frazier Investment Counseling LLC raised its position in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Columbia Wanger Asset Management LLC raised its position in Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares in the last quarter. ProShare Advisors LLC raised its position in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares in the last quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.